Results 201 to 210 of about 592,196 (366)

Matrix Type Influences the Levels of Soluble Immune Checkpoints

open access: yesJournal of Clinical Laboratory Analysis, EarlyView.
This study aimed to assess whether the quantification of soluble immune checkpoints (sICs) is comparable between serum and EDTA‐plasma samples. We quantified 17 sICs by a multiplex bead‐based assay in paired serum and plasma‐EDTA samples collected from a cohort of 38 healthy subjects.
Veronica Buia   +7 more
wiley   +1 more source

Ascitic fluid concentrations of fibronectin and cholesterol [PDF]

open access: yes, 1990
Gerbes, Alexander L.   +3 more
core  

Clinical Implications of Ki‐67 Index, Grade and Hormonal Changes in Pancreatic Neuroendocrine Tumors: Insights Into Tumor Heterogeneity Based on Primary and Secondary Lesions

open access: yesJournal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background Pancreatic neuroendocrine tumors (PanNETs) show heterogeneity, including temporal shifts in proliferation and hormone production; however, their clinical implications remain uncertain. Methods This retrospective study included 114 patients with metastatic or recurrent PanNETs at Kyushu University Hospital.
Masatoshi Murakami   +9 more
wiley   +1 more source

Neoadjuvant Chemotherapy With Gemcitabine/Cisplatin/S‐1 for Resectable Biliary Tract Cancer With FDG‐PET‐Positive Lymph Node Metastasis (KHBO1201): A Multicenter Phase II Trial

open access: yesJournal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Purpose To evaluate the safety and efficacy of neoadjuvant gemcitabine, cisplatin, and S‐1 (GCS) chemotherapy for resectable biliary tract cancer (BTC) and FDG‐PET‐positive lymph nodes in a multicenter phase II study (KHBO1201). Methods Patients with resectable BTC (intrahepatic/extrahepatic bile duct, gallbladder, or ampullary cancers) and ...
Satoshi Ogiso   +9 more
wiley   +1 more source

Clinical analysis of 255 children with multiple serous effusions. [PDF]

open access: yesAnn Med
Jin W   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy